Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.

SOPHiA GENETICS SA

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BOSTON AND ROLLE, SWITZERLAND, JULY 21, 2026 /PRNEWSWIRE/ -- SOPHIA GENETICS (NASDAQ: SOPH), A GLOBAL LEADER IN AI-DRIVEN PRECISION MEDICINE, TODAY ANNOUNCED IT WILL RELEASE ITS FINANCIAL RESULTS FOR THE SECOND QUARTER 2026 BEFORE U.S. MARKETS OPEN ON TUESDAY, AUGUST 4, 2026. ON THAT DAY, SOPHIA GENETICS WILL HOST A CONFERENCE CALL TO DISCUSS ITS FINANCIAL RESULTS AS WELL AS BUSINESS OUTLOOK BEGINNING AT 8:00 A.M.

SOPHIA GENETICS TO ANNOUNCE FINANCIAL RESULTS FOR SECOND QUARTER 2026 ON AUGUST 4, 2026

SHAREHOLDERS ADOPT ALL PROPOSALS, CO-FOUNDER DR. JURGI CAMBLONG ELECTED AS EXECUTIVE CHAIRMAN OF THE BOARD, ROSS MUKEN ELECTED AS NEW MEMBER OF THE BOARD AHEAD OF HIS APPOINTMENT AS CEO EFFECTIVE JULY 1, 2026 ROLLE, SWITZERLAND, JUNE 22, 2026 /PRNEWSWIRE/ -- SOPHIA GENETICS (NASDAQ: SOPH), A GLOBAL LEADER IN AI-DRIVEN PRECISION MEDICINE, TODAY ANNOUNCED THAT ITS 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS ADOPTED ALL PROPOSALS ON THE AGENDA, ELECTING DR. JURGI CAMBLONG AS THE EXECUTIVE CHAIRMAN OF THE BOARD OF DIRECTORS WITH 99.79% OF THE VOTES, AND ROSS MUKEN AS A MEMBER OF THE BOARD OF DIRECTORS FOR THE FIRST TIME WITH 99.88% OF THE VOTES. MR. MUKEN WILL ASSUME THE ROLE OF CHIEF EXECUTIVE OFFICER, EFFECTIVE JULY 1, 2026.

SOPHIA GENETICS PUBLISHES RESULTS OF THE 2026 ANNUAL GENERAL MEETING

BOSTON AND ROLLE, SWITZERLAND, JUNE 19, 2026 /PRNEWSWIRE/ -- SOPHIA GENETICS (NASDAQ: SOPH), A GLOBAL LEADER IN AI-DRIVEN PRECISION MEDICINE, ANNOUNCED TODAY THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING WITH TOTAL GROSS PROCEEDS OF $57.5 MILLION, BEFORE DEDUCTING THE UNDERWRITING DISCOUNTS AND COMMISSIONS AND ESTIMATED OFFERING EXPENSES PAYABLE BY THE COMPANY. AS A RESULT OF STRONG INVESTOR DEMAND, THE OFFERING WAS OVERSUBSCRIBED, AND THE UNDERWRITERS FULLY EXERCISED THEIR OPTION TO PURCHASE AN ADDITIONAL 1,578,900 ORDINARY SHARES AT THE PUBLIC OFFERING PRICE, LESS THE UNDERWRITING DISCOUNTS AND COMMISSIONS.

SOPHIA GENETICS ANNOUNCES CLOSING OF $57.5 MILLION PUBLIC OFFERING OF ORDINARY SHARES WITH FULL EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES

BOSTON AND ROLLE, SWITZERLAND, JUNE 16, 2026 /PRNEWSWIRE/ -- SOPHIA GENETICS (NASDAQ: SOPH), A GLOBAL LEADER IN AI-DRIVEN PRECISION MEDICINE, ANNOUNCED TODAY THE PRICING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 10,526,000 ORDINARY SHARES AT A PUBLIC OFFERING PRICE OF $4.75 PER ORDINARY SHARE. THE GROSS PROCEEDS FROM THE OFFERING, BEFORE DEDUCTING THE UNDERWRITING DISCOUNTS AND COMMISSIONS AND ESTIMATED OFFERING EXPENSES PAYABLE BY THE COMPANY ARE EXPECTED TO BE APPROXIMATELY $50 MILLION.

SOPHIA GENETICS ANNOUNCES PRICING OF $50 MILLION PUBLIC OFFERING OF ORDINARY SHARES

BOSTONAND ROLLE,SWITZERLAND, JUNE 16, 2026 /PRNEWSWIRE/ -- SOPHIA GENETICS (NASDAQ: SOPH), A GLOBAL LEADER IN AI-DRIVEN PRECISION MEDICINE, ANNOUNCED TODAY THE COMMENCEMENT OF A PROPOSED UNDERWRITTEN PUBLIC OFFERING OF ITS ORDINARY SHARES. THE COMPANY ALSO EXPECTS TO GRANT THE UNDERWRITERS AN OPTION TO PURCHASE UP TO AN ADDITIONAL 15% OF THE ORDINARY SHARES AT THE PUBLIC OFFERING PRICE, LESS THE UNDERWRITING DISCOUNT.

SOPHIA GENETICS ANNOUNCES PROPOSED PUBLIC OFFERING OF ORDINARY SHARES

ROSS MUKEN TO ASSUME THE ROLE OF CHIEF EXECUTIVE OFFICER EFFECTIVE JULY 1, 2026; CO-FOUNDER DR. JURGI CAMBLONG NOMINATED FOR ELECTION AS CHAIRMAN OF THE BOARD BOSTON AND ROLLE, SWITZERLAND, JUNE 10, 2026 /PRNEWSWIRE/ --SOPHIA GENETICS (NASDAQ: SOPH), A GLOBAL LEADER IN AI-DRIVEN PRECISION MEDICINE, TODAY CONFIRMED, AHEAD OF ITS 2026 ANNUAL GENERAL MEETING (AGM) SCHEDULED FOR JUNE 18, 2026, THE LEADERSHIP CHANGES FIRST ANNOUNCED IN JANUARY 2026. THE BOARD HAS APPOINTED ROSS MUKEN, CURRENTLY PRESIDENT, AS CHIEF EXECUTIVE OFFICER, EFFECTIVE JULY 1, 2026, AND NOMINATED HIM FOR ELECTION AS A MEMBER OF THE BOARD OF DIRECTORS.

SOPHIA GENETICS CONFIRMS LEADERSHIP TRANSITION AHEAD OF 2026 ANNUAL GENERAL MEETING

SOPHIA GENETICS AND MEMORIAL SLOAN KETTERING CANCER CENTER AIM TO ESTABLISH PRECISION MEDICINE HUB FOR THE NEXT GENERATION OF PRECISION ONCOLOGY NEW YORK, JUNE 4, 2026 /PRNEWSWIRE/ -- SOPHIA GENETICS (NASDAQ: SOPH) TODAY ANNOUNCED THAT THE COMPANY HAS SIGNED A MEMORANDUM OF UNDERSTANDING (MOU) WITH MEMORIAL SLOAN KETTERING CANCER CENTER (MSK) RELATING TO THE FORMATION OF A JOINT VENTURE BETWEEN THE TWO INSTITUTIONS. THE JOINT VENTURE AIMS TO BUILD UPON THE STRENGTH OF MSK INNOVATION IN CLINICAL DIAGNOSTICS AND SOPHIA GENETICS'S AI PLATFORM TO POTENTIALLY DISCOVER, DEVELOP, AND DEPLOY A NEW GENERATION OF PRECISION ONCOLOGY TO PATIENTS AROUND THE WORLD.

SOPHIA GENETICS SIGNS STRATEGIC COLLABORATION MOU WITH LEADING GLOBAL CANCER CENTER

LONDON, MAY 13, 2026 /PRNEWSWIRE/ --SOPHIA GENETICS (NASDAQ: SOPH), A GLOBAL LEADER IN AI-DRIVEN PRECISION MEDICINE, TODAY ANNOUNCED A PARTNERSHIP WITH SYNNOVIS, ONE OF ENGLAND'S LEADING PATHOLOGY PROVIDERS, TO BRING LIQUID BIOPSY TESTING TO LUNG AND BREAST CANCER PATIENTS ACROSS THE U.K. AS PART OF NHS ENGLAND'S 'REVOLUTIONARY BLOOD TEST-FIRST' PROGRAM. SYNNOVIS, A MAJOR PROVIDER FOR ENGLAND'S SOUTH EAST GENOMIC MEDICINE SERVICE, WORKED WITH SOPHIA GENETICS TO LAUNCH THE LIQUID BIOPSY TEST MSK-ACCESS POWERED WITH SOPHIA DDM.

SYNNOVIS AND SOPHIA GENETICS PARTNER TO BRING BLOOD-BASED CANCER TESTING TO PATIENTS ACROSS THE U.K.

BOSTON AND ROLLE, SWITZERLAND, MAY 5, 2026 /PRNEWSWIRE/ -- SOPHIA GENETICS (NASDAQ: SOPH), A GLOBAL LEADER IN AI-DRIVEN PRECISION MEDICINE, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026. FIRST QUARTER 2026 FINANCIAL RESULTS REVENUE WAS $21.7 MILLION, UP 22% YEAR-OVER-YEAR GROSS MARGIN WAS 68.0% ON A REPORTED BASIS AND 75.4% ON AN ADJUSTED BASIS, COMPARED TO 68.7% REPORTED AND 75.7% ADJUSTED IN THE PRIOR YEAR PERIOD IFRS NET LOSS WAS $19.3 MILLION, AN INCREASE OF 11% YEAR-OVER-YEAR; ADJUSTED EBITDA LOSS WAS $9.2 MILLION, IMPROVING 3% YEAR-OVER-YEAR "WE STARTED 2026 STRONG, DELIVERING 22% YEAR-OVER-YEAR REVENUE GROWTH AND A RECORD 108,000 GENOMIC ANALYSES ON SOPHIA DDMTM," SAID JURGI CAMBLONG, PHD.

SOPHIA GENETICS REPORTS FIRST QUARTER 2026 RESULTS

BOSTON AND ROLLE, SWITZERLAND, APRIL 21, 2026 /PRNEWSWIRE/ -- SOPHIA GENETICS (NASDAQ: SOPH), A GLOBAL LEADER IN AI-DRIVEN PRECISION MEDICINE, TODAY ANNOUNCED IT WILL RELEASE ITS FINANCIAL RESULTS FOR THE FIRST QUARTER 2026 BEFORE U.S. MARKETS OPEN ON TUESDAY, MAY 5, 2026. ON THAT DAY, SOPHIA GENETICS WILL HOST A CONFERENCE CALL TO DISCUSS ITS FINANCIAL RESULTS AS WELL AS BUSINESS OUTLOOK BEGINNING AT 8:00 A.M.

SOPHiA GENETICS SA

SOPH

Price

Financial Reports

No items found.

Press Releases

SOPHiA GENETICS SA

SOPH.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

SOPH